Krista Rossi

The FDA has granted an orphan drug designation to MediciNova Inc.’s MN-166, an adjunctive therapy to temozolomide treatment for patients with glioblastoma.

The FDA has granted an orphan drug designation to Eidos Therapeutics, Inc.’s investigational treatment, AG10, for the treatment of transthyretin amyloidosis.

High-risk individuals, such as those with cardiopulmonary and other chronic conditions, are protected from flu-related hospitalizations with the vaccine.

The FDA has approved emicizumab (Hemilbra) for the treatment of hemophilia A without factor VIII inhibitors.

The FDA has approved Genentech’s emicizumab (Hemilbra) for the treatment of hemophilia A without factor VIII inhibitors.

Unvaccinated individuals can also benefit from the flu vaccine.

Positive interim clinical data from Genentech’s 2-part pivotal FIREFISH and SUNFISH trials evaluating risdiplam (RG7916), a potential spinal muscular atrophy (SMA) treatment, have been released.

Mount Sinai investigators have found that anti-A4B7 therapy—specifically, vedolizumab—may represent a new therapeutic approach, prompting a couple of phase 1 clinical trials.

Investigators have found the IIV4 vaccination to be as effective as IIV3-SD, while IIV3-HD was found to be more effective than IIV3-SD.

In a pivotal phase 3 trial, patients' absolute change in facial inflammatory lesion counts included a least squares mean difference of -5.2 compared to those on placebo.

Upon finding pH and oxygen may influence how antibiotics perform in CF lung infections, investigators suggest a one-size-fits-all therapy approach may not be the best treatment.

The FDA has approved amikacin liposome inhalation suspension (Arikayce) for the treatment of lung disease caused by Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).

The pulmonologist and senior medical advisor, American Lung Association, highlights the necessary steps of smoking cessation practices as well as the unknown surrounding e-cigarettes.

The new document will provide guidance on how and when the FDA intends to collect, compile, and publicize retail consignees that may have received recalled foods.

Updates in trivalent vaccines and vaccination clearance for egg-allergic patients were among the updated recommendations for pediatric influenza prevention and treatment this upcoming 2018-2019 flu season.

A 16,000-patient assessment found that infection alone, excluding critical illness, is associated with reduced brain volume later in life.

Robert J. Kreitman, MD, discusses the FDA’s recent approval of moxetumomab pasudotox (Lumoxiti) for the treatment of hairy cell leukemia (HCL).

The FDA has granted an orphan drug designation to Q Therapeutics Inc.’s Q-Cell for the treatment of transverse myelitis.

The FDA has granted an orphan drug designation to Portola Pharmaceuticals’ investigational oral Syk/JAK inhibitor, cerdulatinib, for the treatment of peripheral T cell lymphoma.

The US FDA has granted an orphan drug designation to Cellectar Biosciences, Inc.’s CLR 131 for the treatment of pediatric osteosarcoma.

Pediatric traumatic brain injuries were found to be associated with a variety of health conditions and states with greater levels of private insurance and insurance adequacy.

The FDA has granted an orphan drug designation to Myelo Therapeutics GmbH’s Myelo001 for the treatment of acute radiation syndrome.

The FDA has approved duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies and adult patients with relapsed or refractory follicular lymphoma after at least 2 prior systemic therapies.

Investigators have found that the higher the symptom burden, the greater the detrimental impact on work productivity and daily activity for patients with myeloproliferative neoplasms.

A comparative study found that online prevention programs are just as effective and have higher participation rates compared to in-person programs.

Tumor regressions were observed in 2 of the first 4 evaluable patients in the ongoing phase 2 trial evaluating DPX-Survivac in combination with low dose cyclophosphamide and pembrolizumab.

A software correction is currently being developed to address its inability to start therapy for patients at altitudes above 3200 feet.

Pauline Funchain, MD, highlights how humility may be one of the best characteristics in medicine right now.

Over 12 months of follow-up in the PROOF registry, pulmonary function remained largely stable in patients with idiopathic pulmonary fibrosis who received pirfenidone treatment.

Fingolimod has been linked with a lower rate of relapse and less accumulation of lesions on MRI over a 2-year period compared with interferon beta-1a in a phase 3 PARADIGMS trial.